Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Yuhan Corporation
YH25448 is an oral, highly potent, mutant-selective and irreversible EGFR Tyrosine-kinase inhibitors (TKIs) that targets both the T790M mutation and activating EGFR mutations while sparing wild type EGFR.
This is a Phase III, Randomized, Double-blind study evaluating the efficacy and safety of YH25448 (240 mg orally, once daily) versus Gefitinib (250 mg orally, once daily) in patients with locally advanced or metastatic NSCLC that is known to be EGFR sensitizing mutation (EGFRm) positive, treatment-naïve and eligible for first-line treatment with an EGFR-TKI.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Pathologically confirmed adenocarcinoma of the lung
Locally advanced or metastatic NSCLC, not amenable to curative surgery or radiotherapy
At least 1 of the 2 common EGFR mutations known to be associated with EGFR TKI sensitivity (Ex19del or L858R), either alone or in combination with other EGFR mutations
Treatment-naïve for locally advanced or metastatic NSCLC
WHO performance status score of 0 to 1 with no clinically significant deterioration over the previous 2 weeks before randomization
At least 1 measurable lesion, not previously irradiated and not chosen for biopsy during the study Screening period
You may not be if
Symptomatic and unstable brain metastases
Leptomeningeal metastases
Symptomatic spinal cord compression
History of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD
Any medical conditions requiring chronic continuous oxygen therapy
History of any malignancy other than the disease under study within 3 years before randomization
Any cardiovascular disease as follows:
* History of symptomatic chronic heart failure or serious cardiac arrhythmia requiring active treatment
* History of myocardial infarction or unstable angina within 24 weeks of randomization